Lilly’s New Immunotherapy Taltz® (ixekizumab) Receives FDA Approval for Plaque Psoriasis Treatment


Eli Lilly and CompanyUS Food and Drug Administration (FDA) approved Eli Lilly‘s new immunotherapy Taltz® (ixekizumab) for the treatment of moderate to severe plaque psoriasis.

Taltz® (ixekizumab) injection (80 mg/ml) got approval for the treatment of moderate to severe plaque psoriasis in adult patients who are undergoing regular phototherapy. Taltz is specifically designed to target the protein IL-17A that plays a major role in the underlying inflammation in psoriasis; it is designed to inhibit the activity of this protein so as to cease the inflammation.

Psoriasis is chronic immune disease of skin and plaque psoriasis is the most frequently occurring form of psoriasis. The symptoms of this disease are red patches over skin covered with silvery or white buildup of dead skin cells. These marks are often itchy and painful. The precise causes of this disease are still unknown but genetic and environmental factors are considered to play a role in development of this disease.

Primary reason for the approval of taltz by FDA was based on the observations of this largest study- Phase III trial conducted in 21 countries and includes approximately 3,800 patients from different regions. The efficacy and safety of taltz was demonstrated by this clinical program that three double-blind, multicenter, Phase III studies—UNCOVER-1, UNCOVER-2 and UNCOVER-3. All three studies evaluated and computed the efficacy and safety of taltz compared to placebo after 12 weeks. UNCOVER-2 and UNCOVER-3 included an additional comparator arm in which patients received U.S. FDA approved etanercept (50 mg twice a week) for 12 weeks. UNCOVER-1 and UNCOVER-2 also evaluated response rates with taltz during the maintenance period through 60 weeks.

Though Lilly claims complete clearance of skin in every 4 out of 10 patients due to treatment with taltz but there are some side effects associated with the use of this drug. There is a chance that treatment with taltz lead to increased risk of infections in the patient.

This drug will be available in United States by the beginning in the second quarter of 2016.

Featured image credit: Graphics remixed by Psoriasis On Elbows © Hriana (Stock Photo ID: 68407411)

Leave a reply

Your email address will not be published. Required fields are marked *